Elevance Health, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the Annual Meeting of Shareholders held by Elevance Health, Inc. on May 10, 2023. The filing details the voting outcomes for director elections, executive compensation matters, auditor ratification, and shareholder proposals.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting results.
Material Changes and Voting Results
- Election of Directors: All four nominees (Gail K. Boudreaux, R. Kerry Clark, Robert L. Dixon, Jr., and Deanna D. Strable) were elected to three-year terms expiring in 2026. Robert L. Dixon, Jr. received the highest number of "Against" votes (7,313,382) among the nominees.
- Executive Compensation (Say-on-Pay): The advisory vote on executive compensation was approved with 187,532,307 votes "For" and 11,449,434 votes "Against".
- Compensation Vote Frequency: Shareholders voted to hold the advisory vote on executive compensation annually ("1 Year"), with 196,348,094 votes in favor.
- Auditor Ratification: The appointment of Ernst & Young LLP as the independent registered public accounting firm for 2023 was ratified with 197,125,231 votes "For".
- Shareholder Proposals:
- Right to Call Special Meeting: A proposal allowing shareholders owning 10% or more to call a special meeting was not approved (91,711,541 For vs. 107,655,455 Against).
- Third-Party Financial Support Reporting: A proposal requesting annual reporting on third parties seeking financial support was not approved (16,060,203 For vs. 181,759,805 Against).
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on financial performance, or specific risk factors beyond the standard disclosure of voting results.
Key Facts for Investor Verification
- Verify the specific reasons for the significant "Against" votes on Director Robert L. Dixon, Jr. compared to other nominees.
- Confirm the Board's rationale for rejecting the shareholder proposal regarding the right to call a special meeting, which received substantial support (approx. 46% of votes cast).
- Review the full proxy statement for details on the executive compensation package that was approved by shareholders.
- Note that the company has committed to an annual frequency for executive compensation advisory votes.